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Boston, Massachusetts 02215 The basic mechanisms underlying vasculogenesis
‡Department of Radiation Oncology and angiogenesis are not well understood. Although a
Massachusetts General Hospital variety of factors may be capable of positively and nega-
Boston, Massachusetts 02114 tively regulating endothelial growth and vessel formation
(Hanahan and Folkman, 1996), only vascular endothelial
growth factor (VEGF) has been shown definitively to be
Summary involved during normal embryonic vascular formation
(Fong et al., 1995; Shalaby et al., 1995; Carmeliet et al.,
Vascular endothelial growth factor (VEGF), which acts 1996a; Ferrara et al., 1996). VEGF acts by stimulating
via members of a family of endothelial-specific recep- members of a family of largely endothelial-specific re-
tor tyrosine kinases, is the only factor that has been ceptor tyrosine kinases that includes Flk-1/KDR/VEGF-
shown definitively to play a role in the formation of R2, Flt-1/VEGF-R1, and Flt-4/VEGF-R3 (Mustonen and
the embryonic vasculature. Only one other family of Alitalo, 1995). Although it has long been known that
receptor tyrosine kinases, comprising TIE1 and TIE2, exogenously added VEGF has the ability to promote
is largely endothelial cell specific. We have recently angiogenesis, thecritical roles of VEGF and its receptors
cloned a ligand for TIE2, termed Angiopoietin-1. Here during normal embryogenesis have only recently been
we show that mice engineered to lack Angiopoietin-1 confirmed using mutant mice with targeted gene disrup-
display angiogenic deficits reminiscent of those pre- tions for VEGF and either Flk-1 or Flt-1 (Fong et al., 1995;
viously seen in mice lacking TIE2, demonstrating that Shalaby et al., 1995; Carmeliet et al., 1996a; Ferrara et
Angiopoietin-1 is a primary physiologic ligand for TIE2
al., 1996). Mice lacking Flk-1 fail to develop endothelial
and that it has critical in vivo angiogenic actions that cells, perhaps owing to lack of differentiation of a com-
are distinct from VEGF and that are not reflected in
mon progenitor of the endothelial and hemopoietic lin-the classic in vitro assays used to characterize VEGF.
eages, the hemangioblast (Shalaby et al., 1995). TheAngiopoietin-1 seems to play a crucial role in mediat-
absence of even the earliest vasculogenic events ining reciprocal interactions between the endothelium
these mice verifies the critical role of Flk-1 in initial endo-and surrounding matrix and mesenchyme.
thelial cell differentiation (Shalaby et al., 1995). Mice
homozygous for a null mutation in the VEGF gene doIntroduction
undergo some endothelial cell differentiation, although
this differentiation clearly is abnormal, as seen by theDuring embryonic development, early formation of a
death of the mice early in development (Carmeliet et al.,functioning cardiovascular system is required to support
1996a); the more severe phenotype of mice lacking Flk-1the increasing metabolic demands of the growing em-
suggests additional VEGF-like ligands for this receptor.bryo. The first components of the cardiovascular system
Remarkably, mice heterozygous for the VEGF gene dis-to undergo differentiation are the endothelial cells,
ruption also dieby embryonic day 10.5 (E10.5) (Carmelietwhich are initially involved in all aspects of vascular
et al., 1996a) or E11.5 (Ferrara et al., 1996), indicatingpatterning and which ultimately will line the internal sur-
a critical dose-dependent embryonic requirement forfaces of all vascular structures. The vasculature forms
VEGF. These embryos exhibit substantially more vascu-by two distinct processes, termed vasculogenesis and
lar development than do mice homozygous for eitherangiogenesis (Risau, 1991; Risau, 1995; Patan et al.,
the Flk-1 or VEGF mutations, allowing observations of1996a, 1996b). Vasculogenesis involves the in situ differ-
defects in both vasculogenesis and angiogenesis andentiation of endothelial cells from mesodermally derived
thus demonstrating a role for VEGF in both of theseprecursors and the assembly of these differentiating
processes (Carmeliet et al., 1996a; Ferrara et al., 1996).endothelial cells into discrete blood vessels. Vasculo-
There is only one other family of receptor tyrosinegenesis results in the formation of the primordia of the
kinases, other than the VEGF receptor family, that isheart and large vessels as well as a rather homogenous
known to berather specifically expressed in the vascularprimary capillary network found in both the embryo and
endothelium (Dumont et al., 1992; Partanen et al., 1992;extraembryonic structures such as the yolk sac. Angio-
Iwama et al., 1993; Maisonpierre et al., 1993; Sato et al.,genesis involves the proliferation and migration of endo-
1993; Schnurch and Risau, 1993; Ziegler et al., 1993).thelial cells found in the primary vascular structures and
There are two members in this receptor family, termedleads both to a sprouting into previously avascular or-
TIE1 and TIE2 (also known as TEK). The onset of embry-gans such as the brain and kidney as well as to growth
and remodeling of the initially homogenous capillary onic expression for these receptors seems to follow that
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of the VEGF receptors (Dumont et al., 1995). The recent
generation of mice lacking either TIE1 or TIE2 has re-
vealed the critical requirement of these receptors during
embryonic blood vessel formation (Dumont et al., 1994;
Puri et al., 1995; Sato et al., 1995). Mice lacking TIE2
are more severely affected and die between E9.5 and
E10.5, while mice lacking TIE1 die between E13.5 and
P0. In contrast to the early defects in vasculogenesis
displayed by VEGF- or VEGF receptor–deficient em-
bryos, mice lacking either TIE1 or TIE2 exhibit later de-
fects in angiogenesis and vascular remodeling as well
as in vessel integrity, indicating that the primary roles
of the TIEs are later than those of the VEGF family.
In an accompanying article, we describe identification
and cloning of a novel ligand that specifically binds and
induces tyrosine phosphorylation of TIE2 (Davis et al.,
1996 [this issue of Cell]). This ligand, termed Angiopoie-
tin-1, appears to represent the first member of a new
growth factor–like family specific for the TIE receptors.
However, addition of this ligand to endothelial cell cul-
tures does not promote in vitro responses, such as pro-
liferation and tubule formation, previously observed with
VEGF and other classic endothelial cell growth factors
(Davis et al., 1996). To try to elucidate the normal physio-
logic role of Angiopoietin-1, we engineered mice lacking
Angiopoietin-1 expression. These mice display deficits
in vascular development that are reminiscent of but
slightly less severe than those seen in mice lacking TIE2.
Our results indicate that Angiopoietin-1 is indeed a pri-
mary physiologic ligand for TIE2; that it has critical in
vivo actions during angiogenesis that appear to occur
later than those of VEGF; and that these in vivo actions
are not reflected in the classic in vitro assays used to
characterize VEGF and other endothelial cell growth fac-
tors but instead involve regulation of the interaction of
endothelial cells with the surrounding mesenchymalFigure 1. Generation and Analysis of Mice with Targeted Mutations
of the Angiopoietin-1 Gene cells and the extracellular matrix.
(A) Angiopoietin-1 gene targeting. (a) The genomic structure of the
Angiopoietin-1 gene in the region spanning the first coding exon Results
(black box). The sizes of the restriction fragments resulting from a
Spe1 or an R1 digest as well as DNA probes used in genotyping
Homologous Recombination to Disruptare indicated. (b)The first targeting vector, V1.The 59 3.0 kb genomic
the Mouse Angiopoietin-1 Genefragment containing Not1 sites on either end (the 59 Not1 site was
To construct targeting vectors that could produce nullderived from the polylinker of the l FixII phage clone from which
this fragment was obtained, whereas the 39 Not1 site was introduced mutant alleles for Angiopoietin-1 by homologous recom-
using a linker) was placed into a Not1 site upstream of the promot- bination, we first molecularly cloned and characterized
erless lacZ and PGK-neo cassette, while a 3.5 kb Pml1-H3 fragment the mouse genomic region spanning the first Angiopoie-
(in which H3 linkers were used to modify the 59 end) was cloned
tin-1 coding exon containing the translation initiationinto a Hind3 site between the PGK-neo and tk genes. In this targeting
codon as well as the following signal peptide–encodingvector, 6.3 kb of the Angiopoietin-1 gene, which included sequences
of the first coding exon up to the Pml1 site, were deleted. (c) The
resulting mutant allele after homologous recombination with the V1
vector and the sizesof the Spe1 andR1 fragmentsused for genotyping.
(d and e) The second targeting scheme, in which LacZ expression such targeting. Sites that are lost during vector construction are
is driven off the Angiopoietin-1 promoter. A 59 7.4 kb Not1 fragment shown in parentheses. S, SpeI; H, Hind3; R, EcoRI; P, Pml1.
(the 59 Not1 site was derived from the polylinker of the l FixII phage (B) Southern analyses. (Top and middle) Southern analysis of the
clone from which this fragment was obtained, whereas the 39 Not1 ES cell clones, using the 59 and 39 probes depicted in (A), demon-
site was introduced using a linker to convert the preexisting Spe1 strates that ES clones 74 and 81 have undergone the predicted
site) was placed into a Not1 site upstream of the promoterless lacZ homologous recombination. (Bottom) Southern analysis of DNA
and PGK-neo cassette, placing the lacZ gene in the 59 untranslated from F2 progeny reveals that the targeted allele was transmitted
region of the first exon of Angiopoietin-1 (deleting only a 285 bp and resulted in progeny heterozygous orhomozygous for the mutant
region, from the Spe1 to the Pml1 sites, that removes the ATG and allele. The DNA was isolated from the yolk sacs of E10.5 embryos,
the first 74 amino acids of Angiopoietin-1) and thus allowing the with the midday of the plug observation taken as day 0.5.
Angiopoietin-1 promoter to drive LacZ expression. The 39 3.5 kb (C) Northern analyses. Ten micrograms of total RNA prepared from
Pml1-H3 fragment was cloned as described above for vector V1. (e) wild-type, Angiopoietin-11/2, and Angiopoietin-12/2 F2 progeny
The mutant allele generated following homologous recombination of (E10.5) was probed for the indicated transcripts. Transcript size is
this vector, along with the Spe1 and R1 fragments resulting from shown at the right.
Requisite Role of Angiopoietin-1 during Angiogenesis
1173
sequence (Figure 1A). Two different targeting vectors
were constructed in which theAngiopoietin-1 translation
initiation site and the following signal peptide–encoding
sequences werereplaced by a promoterless b-galactos-
idase (lacZ) gene as well as the neomycin-resistance
(neo) gene driven by a generally active promoter (PGK-
neo). In the first construct, the replacement extended
about 6.3 kb upstream of the exon and removed the
putative Angiopoietin-1 promoter sequences and tran-
scription start sites (Figure 1A, a–c). In the second con-
struct, the promoterless lacZ was inserted into the 59
noncoding region of the first coding exon, allowing LacZ
to be expressed from the endogenous Angiopoietin-1
promoter region (Figure 1A, d and e). Southern blot anal-
ysis revealed that successful targeting of the endoge-
nous Angiopoietin-1 genetic locus was achieved in both
cases (Figure 1B and data not shown). Using a double
selection scheme intended to enhance the selection of
targeted clones, we found 4 of 77 embryonic stem (ES)
cell clones from the first construct and 1 of 113 ES
clones from the second construct to be correctly tar-
geted (Figure 1B). The E14 ES cells that were used were
derived from the 129 strain of mice. Male chimeras de-
rived from all five targeted clones were bred to C57BL/6
females. Chimeras from three of these clones transmit-
ted the mutant allele to their offspring, which were then
bred further. The F1 heterozygous progeny were viable,
appeared normal, and were fertile.
Angiopoietin-1 Gene Disruption Results
in Embryonic Lethality
Figure 2. Angiopoietin-12/2 Embryos at Different Embryonic AgesNo newborn pups homozygous for the Angiopoietin-1
Compared to Wild-Type Embryos
gene disruption were found after examining more than
Except in the heart, where Angiopoietin-12/2 embryos show a
ten litters resulting from the breeding of F1 heterozygous growth retardation, these embryos appear relatively normal up to
mice. This finding raised the possibility that the absence E10.5. At later ages, the homozygous embryos begin to appear
of Angiopoietin-1 resulted in embryonic lethality, as pre- deformed (they are aberrantly curved forward owing to decreased
heart size) and are dead by E12.5. The embryos have been stainedviously noted in mice lacking the TIE2 receptor. Exami-
with an anti-PECAM antibody (see ExperimentalProcedures) to visu-nation of litters at early embryonic stages revealed
alize the endothelial vasculature. Arrowheads indicate intersomiticembryos homozygous for the Angiopoietin-1 gene dis-
vessels, which appear to regress with age in Angiopoietin-12/2 em-
ruption (Figure 1B), and further analysis suggested that bryos (also see Figure 3). Ang1, Angiopoietin-1.
embryos generally began to appear grossly abnormal
by day 11 and were dead by E 12.5 (Figure 2). Northern
analysis confirmed the absence of Angiopoietin-1 tran- atrial endothelial lining, features that are associated with
scripts, as determined by a probe for the first coding growth retardation of the heart (Figures 3I and 3J). Very
exon, in embryos homozygous for the Angiopoietin-1 similar defects are seen in the hearts of Angiopoietin-
gene disruption (Figure 1C, top); biochemical and muta- 12/2 embryos. Whole-mount analysis, in which an anti-
tional analyses have demonstrated that deletion of se- body recognizing an endothelial marker (platelet–
quences found on the first exon functionally inactivate endothelial cell adhesion molecule [PECAM] [Baldwin et
Angiopoietin-1 (S. D. et al., unpublished data). Thus the al., 1994]) was used to visualize specifically the vascular
absence of functional Angiopoietin-1 expression results endothelium in the developing heart, revealed an imma-
in embryonic lethality of developing mice. ture and much less intricately folded endocardium in
the Angiopoietin-12/2 embryos as early as E9.5 (Figures
3A–3H). When comparing hearts at any of the depictedProminent Endocardial and Myocardial
Defects in Mice Lacking Angiopoietin-1 ages, it is clear that hearts from Angiopoietin-12/2 mice
reveal less intense and more speckled PECAM stainingMice lacking TIE2 die 1 to 2 days earlier in embryonic
development than those lacking Angiopoietin-1. How- compared to hearts from littermate controls of the same
age. For example, at E11.5 only speckled ventricularever, analysis of embryos lacking Angiopoietin-1 reveals
deficits very reminiscent of those seen in embryos lack- staining in the absence of atrial staining is noted in
an Angiopoietin-12/2 heart, whereas the heart of theing TIE2. The most prominent defect in embryos lacking
TIE2 involves the heart (Sato et al., 1995; Patan et al., littermate control displays intense homogenous staining
of both the ventricle and the atrium (Figures 3E and 3F).submitted); these embryos have a noticeably less com-
plex ventricular endocardium and an almost collapsed Examination of sections from these embryos provides
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an explanation for the decreased staining seen in the
whole-mount preparations of the mutants (Figures 3G
and 3H). The normal hearts exhibit complex myocardial
trabeculations filling the ventricle, and thus in cross sec-
tion the endothelium lining these complex trabecular
folds is seen as numerous little pockets throughout the
ventricle, explaining the dense staining noted in the
whole mounts (Figure 3H). On the other hand, the mutant
hearts are essentially devoid of trabeculae and thus
contain just endothelium lining at the inside surface of
the ventricle, explaining the weak PECAM staining in the
whole mounts (Figure3G). The less complex endocardial
lining in the mutant hearts actually appears collapsed
and retracted from the myocardial wall (Figures 3G–3H),
as has also been noted in the TIE22/2 embryos (Sato et
al., 1995; Patan et al., submitted). This collapse and
retraction may occur in vivo or during tissue preparation
and in either case may reflect poor association between
the endocardium and the underlying matrix (see below).
Consistent with the similar prominent defects in the
hearts of mice lacking Angiopoietin-1 or TIE2, whole-
mount staining analysis for LacZ in 11.5-day embryos
heterozygous for the targeted construct in which LacZ
is driven off the Angiopoietin-1 promoter demonstrates
that Angiopoietin-1 is indeed most prominently ex-
pressed in the developing heart at this developmental
age (Figure 3K); it should be noted that Angiopoietin-1
expression becomes much more widespread later in
development (Davis et al., 1996; Patan et al., submitted).
In situ hybridization analysis performed on embryo sec-
tions reveals that Angiopoietin-1 is highly expressed in
the myocardial wall surrounding the TIE2-expressing
endocardium (Figures 3L and 3M), indicating that Angio-
poietin-1 produced by the myocardium influences the
development of the adjacent endocardium. Since nota-
ble defects are seen in the development of myocardial
trabeculae in Angiopoietin-12/2 hearts (Figures 3G and
3H), it appears as if the lack of Angiopoietin-1 provided
by the myocardium in turn prevents the endocardium
from providing key signals required for normal trabecu-
lar formation, suggesting a crucial interdependency be-
tween these codeveloping structures. Remarkably, the
trabecular defects noted in the Angiopoietin-12/2 hearts
are very reminiscent of those seen in mice lacking neu-
regulin or its receptors (Meyer and Birchmeier, 1995;
Figure 3. Angiopoietin-1 Expression in the Heart, and Specific Heart Gassmann et al., 1995; Lee et al., 1995; Kramer et al.,
Defects in Angiopoietin-12/2 Embryos 1996), where the absence of neuregulin production by
Higher magnification of PECAM-stained embryos demonstrates the the endocardium prevents normal development of the
immature structure of Angiopoietin-12/2 hearts as early as E9.5 (A myocardium expressing neuregulin receptors. The re-
and B). The more speckled staining in E10.5 (C and D) and E11.5 (E ciprocal expression patterns of Angiopoietin-1 and its
and F) hearts of Angiopoietin-12/2 embryos as compared to controls
receptor with that of neuregulin and its receptors sug-reflects a dramatically less intricately folded myocardium lacking
gest that these two growth factor–receptor systems maytrabeculations and thus a less intricately folded endothelium lining
be mediating the reciprocal interactions between thethe myocardium, as also revealed in sections of E10.5 embryos
(G and H; m and e in [G] indicate the simplified myocardium and developing myocardium and endocardium.
endothelium, respectively, seen in the mutant; Tr in [H] indicates
trabeculae of normal heart that are missing in the mutant heart; ec Mice Lacking Angiopoietin-1 Display Generalized
indicates endocardial cushions that are present in both the mutant Defects in Vascular Complexity
and normal hearts). For comparison, the defects seen in the hearts
As inTIE22/2 embryos (Sato etal., 1995), although Angio-of TIE22/2 E10 embryos are depicted (I and J). A whole-mount LacZ
poietin-12/2 embryos display their most prominent de-stain (see Experimental Procedures) of E11.5 embryos heterozygous
for the Angiopoietin-1–targeted allele in which LacZ expression is
under control of Angiopoietin-1 promoter shows that the Angiopoie-
tin-1 promoter is most strongly expressed in the heart at this devel- to the myocardium (L) as opposed to the TIE2 receptor, which is
opmental stage as compared to the nontargeted control on the right restricted to the endocardium (M).
(K). Further in situ hybridization analysis pinpoints this expression Ang1, Angiopoietin-1; V, ventricle; A, atrium.
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fects in endocardial and myocardial development, they
also exhibit other notable defects, resulting in a gener-
ally less complex vascular network. The primary capil-
lary plexus that surrounds the developing forebrain,
which normally develops into a highly branched and
intricate vascular network by E10.5, instead maintains
a relatively immature appearance as vessels remain di-
lated and almost syncitial when viewed in whole mounts
(Figures 4A and 4B; the arrowhead in [A] indicates a
syncitial region that contrasts with the fine vascular net-
work seen in [B]) or in sections (Figures 4C and 4D; note
the large space within vessels in [C] as compared to
[D]). Consistent with the notion that loss of Angio-
poietin-1 leads to defects in vascular organization but
not to changes in total number of endothelial cells,
Northern analysis revealed similar levels of the general
endothelial cell marker, PECAM, in both Angiopoietin-
12/2 and control embryos (Figure 1C). It is noteworthy
that levels of TIE2 mRNA were substantially reduced in
Angiopoietin-12/2 embryos (Figure 1C), suggesting that
Angiopoietin-1 directly regulates expression of its re-
ceptor or that endothelial levels of TIE2 depend on the
organizational state of vascular structures.
By E11.5, extensive vascular branching and remodel-
ing into large and small vessels has occurred in the head
regions of both normal embryos and Angiopoietin-12/2
embryos (Figures 4E and 4F); however, the vessels in
Angiopoietin-12/2 embryos remain much simpler in ap-
pearance, with much less distinction in size between
large and small vessels. There is a reduced number
of large vessels; these vessels are smaller than their
counterparts; and they have fewer and straighter
branches (Figures 4E and 4F; the arrowhead in [F] de-
picts a typical large vessel in the normal embryo, whose
counterparts are much smaller in mutants, and thearrow
in [F] indicates a large meandering branch in the normal
embryo, which is typically absent in mutant embryos).
Similar deficits in complexity are obvious throughout
the embryo, for example in the developing eye (Figures
4G and 4H), in the primitive gut and umbilicalvasculature
(4I and 4J), and in the intersomitic vessels (Figures 4I–
4L). In the case of the intersomitic vessels, there may
be regression of initially formed vessels (compare the Figure 4. Vascular Defects in Many Regions of Angiopoietin-12/2
intersomitic vessels in the 9.5- and 10.5-day embryos Embryos
depicted in Figure 2 with those in the 11.5-day embryos The vasculature in the Angiopoietin-12/2 embryos is notable for
its decrease in complexity, as evidenced by whole-mount PECAMdepicted in Figures 2 and 4). The most striking example
staining in the forebrain (A and B), head region (E and F), eye (Gof a remodeling deficit is perhaps provided by the yolk
and H), umbilical and primitive gut (I and J), intersomitic region (Ksac vasculature (Figures 4M and 4N), as also was noted
and L), and yolk sac (M and N). The dilated appearance of vessels
for the TIE22/2 embryos (Sato et al., 1995); in both cases, in the forebrain is confirmed by sections (C and D). Arrowhead in
it appears as if remodeling of the initially homogeneous (A) indicates syncitial vessels in contrast to the finer vascular net-
capillary network to form both large and small vessels work seen in (B); arrowhead in (F) indicates large vessels whose
does not occur. counterparts are much smaller in size in Angiopoietin-12/2 embryos
(E); arrow in (F) indicates highly branched and meandering interme-The various vascular branching and remodeling de-
diate-size vessels typically not seen in Angiopoietin-12/2 embryosfects observed correlate with Angiopoietin-1 expression
(E); arrowheads in (L) indicate intersomitic vessels that have re-in tissues (mostly of mesenchymal origin) surrounding
gressed in Angiopoietin-12/2 embryos of this age (K; also see Fig-
these vessels (Davis et al., 1996; Patan et al., submitted). ure 2).
Ang1, Angiopoietin-1.
Endothelial Cells in Mice Lacking Angiopoietin-1
Are Aberrantly Rounded and Poorly Associated
electron microscopy. Differences between vessels inwith Periendothelial Cells and Matrix
normal as compared to Angiopoietin-12/2 embryos wereTo understand better the cellular basis of the vascular
most apparent in tissue folds that split the existing ves-defects observed in Angiopoietin-12/2 mice, we exam-
ined embryonic vessels at the ultrastructural level using sel lumen (Figures 5A and 5D; dashed lines demarcate
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Figure 5. Ultrastructural Analysis of Blood
Vessels in Angiopoietin-12/2 Embryos as
Compared to Control Embryos
(A) Typical tissue fold (dashed line), from the
head region of an E11.5 wild-type embryo,
splitting a single vessel lumen into two lumina
to produce branches. The endothelial cells of
the tissue fold aresupported by periendothel-
ial cells and dense clumps of collagen-like
matrix fibers (arrows).
(B) Higher magnification clearly shows the
periendothelial cell and the dense clusters of
collagen-like fibers in the tissue fold of a wild-
type embryo.
(C) An endothelial cell located in a wild-type
vessel with a typically stretched and flattened
appearance.
(D) Shorter tissue fold (dashed line) in a vessel
from a region of an E11.5 Angiopoietin-12/2
embryo that is analogous to the region in the
wild-type embryo shown in (A), depicting en-
dothelial cells stretched to a lesser degree,
lack of periendothelial cells, and matrix fibers
present only sparsely and unclustered. Elec-
tron-dense tight junctions between endothe-
lial cells (asterisk) are normal. (E and F) In
other regions of vessels from Angiopoietin-
12/2 embryos, shown at higher magnification,
the endothelial cells appear more rounded
compared to the flattened endothelial cells
seen in the wild-type embryo; the increased
space underlying endothelial cells is filled
with dispersed collagen-like fibers (arrow);
and periendothelial cells are scarce.
end, endothelial cell, per, periendothelial cell,
epl, epithelial cell, lu, blood vessel lumen;
arrows, collagen-like fibers; arrowheads,
erythrocytes. Scale bar, 1 mm.
tissue folds). These folds are responsible for vessel Thus, the vascular defects noted by PECAM-staining
branching and remodeling, which involves the recruit- of Angiopoietin-12/2 embryosare accompanied by cellu-
ment of periendothelial cells and the organization of lar defects observable at the ultrastructural level. In
matrix elements (such as collagen fibers) (Patan et al., many ways, the defects noted above in terms of endo-
1996a, 1996b, submitted). The endothelial cells in folds cardial and myocardial codevelopment (Figures 3G and
from normal embryos appear thin and flattened and are 3H) may be a particular manifestation in the heart of
associated with the underlying periendothelial cells as a more generalized defect, noted in the ultrastructural
well as with dense clumps of collagen-like fibers (Figures analysis, of the interactions between the endothelium
5A and 5B; arrows indicate collagen-like fibers). These and its surrounding cells and matrix.
are typical tissue folds thought to be involved in vessel
branching (Patan et al., 1996a, 1996b). In contrast, the
Discussionendothelial cells in folds from Angiopoietin-12/2 em-
bryos are less flattened; periendothelial cells are absent;
In an accompanying article we describe the identifica-the collagen-like fibers are individual and scattered; and
tion and cloning of a putative ligand, Angiopoietin-1, forthe folds themselves appear shorter (Figure 5D). After
the TIE2 receptor (Davis et al., 1996). However, Angio-scanning numerous sections to find several tissue folds,
poietin-1 did not induce responses from endothelialit was noted that 0 of 12 tissue folds containedperiendo-
cells in classic in vitro assays previously used to evalu-thelial cells in sections from the Angiopoietin-12/2 em-
ate VEGF and other endothelial cell growth factorsbryos, whereas 12 of 12 tissue folds contained periendo-
(Davis et al., 1996). To try to understand the normalthelial cells in sections from normal embryos.
physiologic role of Angiopoietin-1, we engineered miceIn addition to the prominent defects in tissue folds,
lacking Angiopoietin-1 expression and now report thatAngiopoietin-12/2 embryos also display related defects
these mice display deficits in vascular development thatin other parts of developing vessels. Again, periendo-
are indeed reminiscent of those seen in mice lackingthelial cells are scarce, and instead of being closely
TIE2 (Sato et al., 1995; Patan et al., submitted). Ourapposed to these cells, the relatively rounded endothe-
results thus indicate that Angiopoietin-1 is indeed a pri-lial cells are widely separated from other types of under-
mary physiologic ligand for TIE2. The vascular defectslying cells (such as epithelial cells), and the intervening
in Angiopoietin-12/2 mice appear somewhat less severespace contains scattered collagen-like fibers (compare
Figures 5E and 5F with Figure 5C). than those in TIE22/2 mice. While issues such as precise
Requisite Role of Angiopoietin-1 during Angiogenesis
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genetic background, maternal supply of ligand, or the grosser defects observed, such as the failure in
possibility of ligand-independent receptor function must branching and vessel segmentation, leading to more
be considered, it seems most likely that the differences homogenously dilated vessels. Poor association with
in phenotype are due to the existence of additional li- underlying matrix mayalso adverselyaffect vessel integ-
gands for TIE2; similarly, additional VEGF relatives ap- rity in mice lacking Angiopoietin-1 and may prohibit ap-
parently can explain differences seen between the propriate stabilization and maturation of the vascula-
VEGF2/2 and Flk12/2 mice (Shalaby et al., 1995; Carme- ture. Such a problem may ultimately lead to vessel
liet et al., 1996a). Consistent with this possibility, we regression in some cases, as may be observed for the
have recently identified additional Angiopoietin-1– intersomitic vessels, and perhaps even endothelial cell
related ligands for TIE2 (D. M. Valenzuela et al., unpub- death. The possibility that Angiopoietin-1 acts to regu-
lished data), indicating that Angiopoietin-1 is the first late endothelial–matrix interactions is also consistent
member of a new family of ligands for the TIE receptors. with the expression of Angiopoietin-1 by abluminal cells
Our results indicate that the physiologic roles of the tightly surrounding vessels (see above; Davis et al.,
TIE2 receptor and its ligands are limited to angiogenic 1996; Patan et al., submitted). It is noteworthy that the
processes that occur subsequent to the earlier vasculo- ultrastructural defects noted in Angiopoietin-12/2 ves-
genic and angiogenic actions of the VEGF family and sels are somewhat reminiscent of those recently de-
their receptors. This possibility might have been pre- scribed for mice lacking tissue factor (TF), which seem
dicted by the observation that TIE2 receptor expression to be due to poor pericyte accumulation and function
follows that of Flk-1 by 12–24 hr during embryogenesis that cause problems in the developing vessel wall (Car-
(Dumont et al., 1995) and is similar to the conclusions meliet et al., 1996b); the defects in mice lacking TF are,
reached by analysis of mice lacking the TIE1 and TIE2 like those in Angiopoietin-12/2 mice, more prominent
receptors (Dumont et al., 1994; Puri et al., 1995; Sato in the extraembryonic vasculature, such as yolk sac
et al., 1995). Our findings that Angiopoietin-1 does not vessels. In addition, the defects in Angiopoietin-12/2 and
induce VEGF-like growth and tubule formation re- TF2/2 mice may also be related to thepericyte abnormal-
sponses in vitro are also consistent with later and dis- ity that may contribute to the microaneurysms seen in
tinct roles of Angiopoietin-1 as compared to VEGF diabetic retinopathy (Folkman, 1995). Thus the interac-
(Davis et al., 1996). So what might be the roles of Angio- tions between endothelial cells and the surrounding ma-
poietin-1? While Angiopoietin-1 does not appear to be
trix and mesenchyme appear to be of general impor-
capable of mediating endothelial cell growth or tubule
tance for the formation of a stable vasculature and
formation, mice lacking Angiopoietin-1 seem to exhibit
require the interaction of multiple systems (Ingber and
defects in the remodeling of their vasculature and ap-
Folkman, 1989). Integration may well involve intracellular
pear to have a simplified and less complex vasculature
signaling pathways; GTPase-activating protein and the
containing fewer branches and more homogeneously
Ras pathway may serve as such critical downstreamsized vessels. The defects are most prominent in the
integrators because the prominent remodeling defectsheart, where Angiopoietin-1 expression is the highest
seen in the yolk sac vasculature of both the Angiopoie-in the early stages of development. The absence of
tin-12/2 and TF2/2 mice are also observedin mice lackingAngiopoietin-1 in the heart and its effects on the endo-
GTPase-activating protein (Henkemeyer et al., 1995).cardium seem to result in secondary defects in the ad-
The heart defects seen in the Angiopoietin-12/2 mice,jacent myocardium, resulting in the absence of the
in which myocardial trabecular development is blunted,normally intricately branched and folded myocardial tra-
are remarkably analogous to those described in micebeculations. If the embryos had survived longer, it is
lacking either neuregulin or its receptors (Gassmann etpossible that defects seen in other regions of the body
al., 1995; Lee et al., 1995; Meyer and Birchmeier, 1995;would have become even more severe as well. Consis-
Kramer et al., 1996), which are expressed in reciprocaltent with critical later roles for Angiopoietin-1 elsewhere
fashion in the heart as compared to Angipoietin-1 andin the vasculature, the expression of Angiopoietin-1
its receptor. It is intriguing that the heart defect mayseems to become much more prominent and wide-
simply represent a particular manifestation of the globalspread surrounding blood vessels later in development
disruption of proper interactions between endothelial(Davis et al., 1996; Patan et al., submitted). Alternatively,
cells and their surrounding mesenchyme and matrix. ItAngiopoietin-1 may be required to different degrees in
seems likely that Angiopoietin-1 and neuregulin, in thedifferent vascular beds, depending on its level of expres-
heart, may be two of the crucial reciprocal signals ex-sion as well as that of other vascular modulators.
changed between the developing endocardium andIt seems possible that all of the defects observed in
myocardium.Angiopoietin-12/2 mice result from a problem with a
Our data are consistent with the notion that develop-common underlying process for which Angiopoietin-1 is
ment of the embryonic vasculature depends on the se-normally required. The ultrastructural analysis suggests
quential and cooperative efforts of members of theVEGFthat in the absence of Angiopoietin-1, endothelial cells
family with members of the Angiopoietin-1 family. It alsoare poorly associated with the underlying matrix and do
seems likely that these types of cooperative interactionsnot properly recruit and associate with periendothelial
are required not only for embryonic vascular formationsupporting cells. This failure to associate properly with
but also for angiogenic processes in the adult. Sinceunderlying cells and matrix elements may result in the
Angiopoietin-1 may act rather late to cause maturationother ultrastructural defects observed, such as the lack
and stabilization of vessels in the context of their associ-of spreading and flattening of the endothelial cells, as
ated matrix and surrounding tissues (including perien-well as the poorer tissue folds observed. These ultra-
structural defects may in turn explain some of the dothelial cells), initiation of new angiogenesis in the adult
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of recombinant Angiopoietin-1 should allow the determi-
nation of the physiologic or pharmacologic ramifications
of activating the TIE2 receptor in hemopoietic cells.
The cloning of a biologically relevant ligand for the
TIE2 receptor represents a significant milestone in the
effort to understand how blood vessel formation occurs
and may prove important in hemopoietic research as
well. The availability of recombinant Angiopoietin-1
should allow the establishment of new in vitro and in
vivo models that will address the precise biologic roles
of the TIE receptors and their ligands as well as the
underlying biochemical signaling cascades. Ultimately
it should help lead to an understanding of how the TIEs
and their ligands collaborate with the VEGF family to
form optimally functional blood vessels.
Experimental Procedures
Construction of Targeting Vectors
Figure 6. Schematic Depiction of Defective Vascular Development and ES Cell Manipulations
in the Absence of Angiopoietin-1 The 59 and 39 Angiopoietin-1 gene fragments used in the construc-
tion of the targeting vectors were isolated from a 129SV mouseShown are deficient tissue folds and decreased branching resulting
genomic library in the l FixII vector (Stratagene). In both of thein dilated vessels in the absence of Angiopoietin-1.
constructs (Figure 1A), the 59 fragments (each containing 59 Not1
sites derived from the polylinker of the l FixII phage clone frommay paradoxically require initial down-regulation of TIE-
which these fragments were derived and in which Not1 linkers were
mediated processes to allow new growth of vessels, used to convert the 39 sites) were inserted into a Not1 site upstream
followed by up-regulation of TIE-mediated processes as of a cassette containing a promoterless lacZ gene followed by the
angiogenesis proceeds. There are a variety of important neomycin-resistance gene driven by the phosphoglycerate kinase
promoter (PGK-neo); the lacZ gene, with a modified Kozak se-clinical situations in which it would be desirable to pro-
quence, was a gift from J. Rossant (Mt. Sinai Hospital, Toronto,mote angiogenic processes, such as for induction of
Canada). In the first construct, a 3.0 kb 59 fragment was used thatcollateral vascularization in an ischemic heart or limb
resulted in a 6.3 kb deletion spanning the promoter sequences,
(Ferrara et al., 1995). Conversely, there are pathological the translation initiation site, and the first 74 amino acids of the
situations in which preventing angiogenic processes Angiopoietin-1 gene. In the second construct, a 7.4 kb 59 fragment
could be used to starve a growing tumor or abate a was used that only resulted in a 285 bp deletion in the first exon
raging inflammatory process (Ferrara, 1995; Folkman, (spanning the translation initiation site and the first 74 codons of
the Angiopoietin-1 gene), leaving the lacZ gene inserted into the 591995; Hanahan and Folkman, 1996). While many efforts
untranslated region of the first exon and thus under control of thein promoting or preventing angiogenesis have focused
Angiopoietin-1 promoter sequences. In both constructs, a 3.5 kbon the VEGF family, it now seems clear that any potential
Pml1-Hind3 fragment was then cloned into a Hind3 site between
therapeutic treatments based on VEGF manipulation the PGK-neo and thymidine kinase (tk) genes, using HindIII linkers
must be considered in the context of Angiopoietin-1 to convert the Pml1 site. Both constructs were linearized with a Srf1
(and its relatives), since these two growth factorsystems site in the polylinker upstream of the 59 fragments, electroporated
seem normally to act together for optimal blood vessel into E14.1 ES cells, and subjected to a double selection scheme
using G418 and gancyclovir, which resulted in a 5-fold enrichment.formation (Figure 6). In support of this notion, adminis-
Positive clones were identified by Southern analyses and were usedtration of excess VEGF alone during embryogenesis
to create chimeric mice using standard injection protocols (DeChiaraseems to result in the formation of malformed and hyper-
et al., 1996).
fused vessels analogous to those seen in embryos lack-
ing Angiopoietin-1 (Drake and Little, 1995). Moreover,
Northern Analysisderangements of the Angiopoietin/TIE2 system in hu-
Northern analysis was performed as previously described (Maison-mans, due to a mutation of the TIE2 receptor, lead to
pierre et al., 1993). The Angiopoietin-1 probe was made by PCR
venous malformations deficient in smooth muscle sup- and spanned 241 bp of the first coding exon, a region deleted in
port (Vikkula et al., 1996 [this issue of Cell]), consistent the mutant mice. The PECAM probe (a gift from H. S. Baldwin, Wistar
with our findings suggesting a critical role for Angiopoie- Institute) was 1.6 kb in length, spanning 1.4kb of 39 coding sequence
and 0.2 kb of 39 untranslated sequence. The TIE2 probe was madetin-1 in mediating interactions between endothelial cells
from full-length rat cDNA (Maisonpierre et al., 1993). The GAPDHand supporting mesenchymal elements.
(glyceraldehyde-3-phosphate dehydrogenase) probe was a gift fromIt should also be noted that although the TIE receptors
S. Chen-Kiang (Cornell University Medical College, New York).are largely restricted to endothelial cells in their expres-
sion, they are also expressed in very early cells of the
In Situ Hybridizations and Embryo Stainingshemopoietic lineage (Iwama et al., 1993; Batard et al.,
In situ hybridization analyses using the Angiopoietin-1 or TIE21996; Hashiyama et al., 1996). This expression may re-
probes, whole-mount embryo immunostainings using an anti-flect a common origin of both the hemopoietic and
PECAM antibody (MEC13.3, rat anti-mouse monoclonal; Phar-
angiogenic lineages from a precursor, the hemangio- mingen) and subsequent sectioning of these whole mounts, and
blast (Shalaby et al., 1995). The early death of Angio- whole-mount stainings for LacZ activity were performed as pre-
poietin-1 and TIE22/2 embryos precludes a useful evalu- viously described (Schlaeger et al., 1995; Davis et al., 1996; Patan
et al., submitted).ation of their hemopoietic lineages, but the availability
Requisite Role of Angiopoietin-1 during Angiogenesis
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Electron Microscopic Analysis required for neuromuscular junction formation in vivo. Cell 85,
501–512.E11.5 embryos were dissected and processed for the whole- mount
immunohistochemical staining with anti-PECAM (Schlaeger et al., Drake, C.J., and Little, C.D. (1995). Exogenous vascular endothelial
1995); embryo genotyping was performed on DNA lysates prepared growth factor induces malformed and hyperfused vessels during
from the yolk sac. The whole-mount stained embryos were postfixed embryonic neovascularization. Proc. Natl. Acad. Sci. USA 92, 7657–
in a modified Karnofsky’s fixative (2% paraformaldehyde, 2.5% glu- 7661.
taraldehyde, in 0.1 M cacodylate buffer [pH 7.4]) at 48C overnight.
Dumont, D.J., Yamaguchi, T.P., Conlon, R.A., Rossant, J., and Breit-After the tissues were rinsed with 0.1 M cacodylate buffer several
man, M.L. (1992). Tek, novel tyrosine kinase gene located on mousetimes, they were fixed in 1% osmium tetraoxide in 0.1 M cacodylate
chromosome 4, is expressed in endothelial cells and their presump-buffer for 1 hr. They were subsequently incubated overnight in 2%
tive precursors. Oncogene 7, 1471–1480.aqueous uranyl acetate. On the following day, the tissues were
Dumont, D.J., Gradwohl, G., Fong, G.-H., Puri, M.C., Gerstenstein,dehydrated though an ascending ethanol series, substituted with
M., Auerbach, A., and Breitman, M.L. (1994). Dominant-negative andpropylene oxide, and infiltrated with LX112 resin–propylene oxide
targeted null mutations in the endothelial receptor tyrosine kinase,overnight. The tissues were then embedded in LX112 resin and
tek, reveal a critical role in vasculogenesis of the embryo. Genespolymerized at 608C for 48 hours. Semithin sections were cut on a
Dev. 8, 1897–1909.Reichert ultracut E ultramicrotome at 0.5 mm thickness and stained
with 1% toluidine blue. These semithin sections were observed Dumont, D.J., Fong, G.-H., Puri, M.C., Gradwohl, G., Alitalo, K., and
under the light microscope, and analogous areas between wild-type Breitman, M.L. (1995). Vascularization of the mouse embryo: a study
and mutant embryos were selected for ultrathin sections (75 nm) of flk-1, tek, tie, and vascular endothelial growth factor expression
for electron microscopic analysis. Ultrathin sections were mounted during development. Dev. Dyn. 203, 80–92.
on formvar-coated grids stabilized with carbon and stained with Ferrara, N. (1995). The role of vascular endothelial growth factor in
uranyl acetate and lead citrate. Grids were examined on a JEOL pathological angiogensis. Breast Cancer Res. Treat. 36, 127–137.
100CX electron microscope.
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